Pfizer Inc. $PFE Shares Purchased by Alliancebernstein L.P.

Key Points

• Alliancebernstein L.P. increased its stake in Pfizer by 0.9% in Q1, owning approximately 6.43 million shares valued at about $163 million.
• Securities analysts have mixed views on Pfizer, with a consensus rating of "Hold" and a target price averaging $28.12.
• Pfizer recently reported $0.78 EPS for the quarter, exceeding expectations, and has declared a $0.43 quarterly dividend, yielding 7.0% annually.

Alliancebernstein L.P. boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 0.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,434,377 shares of the biopharmaceutical company's stock after purchasing an additional 59,008 shares during the quarter. Alliancebernstein L.P. owned about 0.11% of Pfizer worth $163,047,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC increased its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter valued at about $27,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the 1st quarter valued at about $28,000. Finally, North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter valued at about $28,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PFE. Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. HSBC cut their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Price Performance

Shares of PFE opened at $24.51 on Friday. The company has a market cap of $139.32 billion, a P/E ratio of 13.03, a PEG ratio of 0.88 and a beta of 0.55. The stock has a fifty day moving average price of $24.83 and a 200 day moving average price of $24.36. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer's dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.